Conjunctival hemorrhagic events associated with imatinib mesylate

International Journal of Hematology

Volumn 86, Issue 5, 2007, Pages 390-393

  Radaelli, Franca ^a   Vener, Claudia ^a   Ripamonti, Francesco ^a   Iurlo, Alessandra ^a   Colombi, Mariangela ^a   Artoni, Andrea ^a   Reda, Gianluigi ^a   Deliliers, Giorgio Lambertenghi ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

CML; Conjunctival hemorrhage; Imatinib; STI571

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONJUNCTIVAL HEMORRHAGE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; ERYTHEMA; EYE IRRITATION; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEMATOMA; HUMAN; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; PERIORBITAL EDEMA; RASH; RECURRENT DISEASE; SKIN PRURITUS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CONJUNCTIVAL DISEASES; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HEMORRHAGE; HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 38349052256     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.E0741     Document Type: Article

References (17)

1. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
2. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104.
3. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 2002;1:31-36.
4. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
5. Talpaz M, Silver RT, Druker B, et al. A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase [abstract]. Blood. 2000;96:470a.
6. Sawyers C, Hochhaus A, Feldman E, et al. A phase 11 study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis [abstract]. Blood. 2000;96:470a.
7. Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. Oncologist. 2001;6:233-238.
8. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effects of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
9. Blanke CD, von Mehren M, Joensuu H, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing c-kit (CD117) [abstract]. Proc Am Soc Clin Oncol. 2001;20:1a.
10. Baccarani M, Martinelli G, Rosti G, et al, for the GIMEMA Working Party on Chronic Myeloid Leukemia. Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia. Blood. 2004;104:4245-4251.
11. Cervantes F, Hernández-Boluda JC, Steegmann JL, et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica. 2003;88:1117-1122.
12. Müller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C. Leukemia. 2003;17:2392-2400.
13. Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 2002;95:881-887.
14. Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003;19:371-375.
15. Esmaeli B, Diba R, Ahmadi MA, et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye. 2004;18:760-762.
16. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med. 1990;88:1-8.
17. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873-2888.